MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:34Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Topical corticosteroids]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #129

2026-05-23T03:51:55Z

parser-claude batch MedTemplate pre-fill, Top 300 #129

New page

{{MedTemplate
| generic = Clobetasol propionate
| brand = Temovate, Clobex, Cormax, Olux, Olux-E, Impoyz
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid]], [[:Category:Topical_corticosteroids|Topical corticosteroid (Class I, super-potent)]]
| uses = <vote slug="severe-dermatitis-use">Severe corticosteroid-responsive dermatoses (psoriasis, lichen planus, lichen sclerosus, severe atopic dermatitis flares)</vote>, <vote slug="oral-lichen-planus-use">Oral lichen planus (topical paste / rinse)</vote>
| starting_dose = Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas
| preparations = Cream, ointment, lotion, foam, solution, shampoo, spray at 0.025-0.05%; emollient and non-emollient bases
| fda_max = 50 g/week (cream/ointment); 2-week continuous limit; 4-week maximum cumulative
| pill_id =
| routes = Topical
| onset = Hours to days for inflammation; substantial improvement within 1 week
| duration = Hours to days per application
| halflife = Not meaningfully described for topical use (systemic exposure varies with surface area, occlusion, skin integrity)<ref name="temovate-label">FDA Prescribing Information, Temovate (clobetasol propionate), GSK, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019322s029,019323s029,019324s029,019325s029lbl.pdf</ref>
| bioavailability = Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas<ref name="temovate-label" />
| pregnancy = Topical corticosteroids in pregnancy: use lowest potency and smallest area; super-potent agents like clobetasol are reserved for compelling indications.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="clobetasol-mech-claim">Clobetasol is a Class I (super-potent) topical glucocorticoid receptor agonist with hundreds-fold higher topical potency than hydrocortisone; activation broadly suppresses inflammatory and immune gene expression in skin.</vote> Characteristic adverse effects with prolonged use or large-area application: skin atrophy, striae, telangiectasia, perioral dermatitis, rebound on discontinuation, HPA suppression, and (rarely) iatrogenic Cushing's. The 2-week limit and the surface-area ceiling are central to safe use<ref name="temovate-label" />.
}}

== References ==
<references />

Clobetasol - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #129